

## CORRECTION


# Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice

Nicole Caduff, Donal McHugh, Anita Murer, Patrick Ramer, Ana Raykova, Vanessa Landtwing, Lisa Rieble, Christian W. Keller, Michael Prummer, Laurent Hoffmann, Janice K. P. Lam, Alan K. S. Chiang, Friedrich Raulf, Tarik Azzi, Christoph Berger, Tina Rubic-Schneider, Elisabetta Traggiai, Jan D. Lunemann, Michael Kammuller, Christian Munz

The following information is missing from the Funding statement: AKSC was supported by a HMRF grant (18170462).

## Reference

1. Caduff N, McHugh D, Murer A, Ramer P, Raykova A, Landtwing V, et al. (2020) Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. *PLoS Pathog* 16(4): e1008477. <https://doi.org/10.1371/journal.ppat.1008477> PMID: 32251475



## OPEN ACCESS

**Citation:** Caduff N, McHugh D, Murer A, Ramer P, Raykova A, Landtwing V, et al. (2020) Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. *PLoS Pathog* 16(12): e1009167. <https://doi.org/10.1371/journal.ppat.1009167>

**Published:** December 21, 2020

**Copyright:**  2020 Caduff et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.